Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Myfortic Conversion in Stable Renal Transplant Patients
NCT00171392Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2004
- Primary completion
- Jun 2005
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of mycophenolate sodium in kidney transplantation, sponsored by Novartis. Primary endpoint: Calculated Creatinine Clearance. Started Mar 2004; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT00171392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171392.